KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources.

• AS
  American Society of Nephrology
• A
  AstraZeneca
• G
  GlaxoSmithKline
• UO
  University of Washington
• BI
  Boehringer Ingelheim
• QM
  Queen Mary University of London
• IS
  International Society of Nephrology
• HK
  Hong Kong Society of Nephrology
• KC
  King's College London
• UD
  Universidad de Buenos Aires
• NI
  National Institutes of Health